In 1,800 patients with diabetes and multivessel coronary disease undergoing PCI, ultra-thin biodegradable-polymer sirolimus-eluting stents were non-inferior to durable-polymer everolimus-eluting stents for 1-year target lesion failure (7.92% vs 8.75%).
RCTn = 1,800
Kaul et al. Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial